Article
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.
Cancer - 1 Apr 2025
Nanni Jacopo, Azzali Irene, Papayannidis Cristina, Mulè Antonino, Audisio Ernesta, Martelli Maria Paola, Scappini Barbara, Chiusolo Patrizia, Cambò Benedetta, Candoni Anna, Lunghi Monia, Albano Francesco, Olivieri Attilio, Fracchiolla Nicola, Bernardi Massimo, Romani Claudio, Rigolin Gian Matteo, Giannini Maria Benedetta, Bocchia Monica, Todisco Elisabetta, Cilloni Daniela, Bochicchio Maria Teresa, Ottaviani Emanuela, Mattei Agnese, Zamagni Federica, Valli Irene, Volpi Roberta, Marconi Giovanni, Petracci Elisabetta, Martinelli Giovanni
Abstract excerpt
BACKGROUND: The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with FLT3-mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence regarding FLT3i adoption in routine clinical practice is still scarce. METHODS: Clinical data are reported from 394 ND patients with FLT3-mutated AML enrolled...
Read the complete abstract on PubMedTopics
- Humans
- fms-Like Tyrosine Kinase 3